from Yahoo Finance https://ift.tt/2XKqkmU
-
PG&E to Sell San Francisco Headquarters, Move to Oakland
-
CSL share price drops lower despite announcing a new acquisition
The CSL Limited (ASX: CSL) share price has continued its poor form and has been unable to climb higher with the market on Tuesday.
This is even after the release of a promising announcement this morning.
At the time of writing the biotherapeutics company’s shares are down 2.5% to $277.99.
What did CSL announce?
This morning CSL announced that it has agreed to exercise its right to acquire clinical-stage biotechnology company Vitaeris.
Vitaeris is currently focused on the phase 3 development of a treatment for rejection in solid organ kidney transplant patients.
Both companies entered into a strategic partnership in 2017 to speed up the development of this program. This partnership included the option for CSL to acquire Vitaeris in full at a later date.
It has now exercised this option, which means Vitaeris’ research assets will now join CSL842 and CSL964 as part of CSL’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.
What is Vitaeris’ treatment?
According to the release, Vitaeris’ lead phase 3 program is investigating the role that a monoclonal antibody called clazakizumab has in treating a naturally occurring inflammatory gene (interleukin6 or IL-6).
This inflammatory gene is the leading cause of long-term rejection in kidney transplant recipients.
CSL’s Executive Vice President and Head of Research and Development, Bill Mezzanotte, spoke positively about the acquisition.
He said: “Clazakizumab has been a promising monoclonal antibody in the Transplant therapeutic area since we started working with Vitaeris several years ago.”
“Acquiring Vitaeris and their associate expertise helps us to continue to grow our strategic scientific platform of recombinant proteins and antibodies. We look forward to continuing to advance this treatment candidate as a potential option for people experiencing rejection, an area where current treatment options for transplant recipients are limited, at best,” he added.
What now?
CSL notes that the cost of acquisition is modest and does not materially change its profit expectation for FY 2020.
The terms of agreement include sales-based milestones and the company will incur additional research and development expenses. These are associated with the completion of the phase 3 clinical trial.
In FY 2021, these additional expenses are estimated to be between US$30 million to US$50 million. While this might seem like a large expense, it isn’t in comparison to its overall research and development spend.
CSL traditionally spends in the region of 11% to 12% of sales on research and development activities. This led to the company pumping US$832 million into these activities in FY 2019.
Looking for more exciting shares to invest in like CSL? Then check out the recommendation below which look like future market beaters…
One trick to potentially generating life-changing wealth from the stock market is to buy early-stage growth companies when their share prices still look dirt cheap.
Motley Fool’s resident tech stock expert Dr. Anirban Mahanti has identified 5 stocks he thinks are screaming buys. And you can buy them now for less than $5 a share!
* Extreme Opportunities returns as of June 5th 2020
More reading
- ASX 200 jumps 2.5%: Big four banks surge higher, CSL announces an acquisition
- Why CSL, Elders, Evolution, & Xero shares are dropping lower
- 2 ASX 200 biotech shares to consider buying today
- ASX 200 Weekly Wrap: ASX bulls crash through 6,000 points
- ASX shares could be the best way to grow your wealth in 2020
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post CSL share price drops lower despite announcing a new acquisition appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/2Yf9JGL
-
Are the Rio Tinto, Fortescue and BHP share prices a buy right now?
The iron ore spot price continues to go from strength to strength, topping US$100 per tonne for the first time this year. China’s iron ore futures market opened more than 6% higher on Monday after top miner Vale SA was ordered to shut operations at a site that accounts for approximately 10% of its output.
Could supply woes make the Rio Tinto Limited (ASX: RIO), Fortescue Metals Group Limited (ASX: FMG) and BHP Group Ltd (ASX: BHP) share prices a buy?
Vale SA to close multiple sites
The Australian Financial Review (AFR) reports that a Brazilian labor court judge ordered Vale SA to close multiple sites after a COVID-19 outbreak among workers.
Investors may remember Vale’s tailings dam collapse in late January 2019. This tragic incident killed 237, left 33 missing and nearly 1,000 displaced. The closure of this mine site resulted in significant supply woes for the global iron ore market. This supply imbalance caused the iron ore spot price to soar from ~US$70 to more than US$120 per tonne in July 2019. This also saw the Rio Tinto, Fortescue and BHP share prices hit record highs or price levels not seen since the GFC.
Australia is the largest iron ore producing country in the world and is also fortunate enough to have largely tackled the spread of the coronavirus. However, other producers that play a vital role in the iron ore supply chain such as Brazil, Russia and India are still at various stages of the curve and ranked 2nd, 4th and 5th, respectively, for active cases globally. This is likely to see an impact on various parts of their economies, including mining.
Aussie miners to benefit
The Rio Tinto, Fortescue and BHP share prices are likely to continue to push higher following strong spot prices. Elevated iron ore prices will continue to support the market-leading dividends paid by Aussie miners. At the time of writing, Rio Tinto currently pays a dividend yield of 5.77%, BHP pays 5.87% and Fortescue pays 6.88%.
From a risk/reward perspective, it may be challenging for investors to buy Fortescue at its current record all-time high prices. Alternatively, I believe it is feasible for the Rio Tinto and BHP share prices to revisit their previous highs. This can be further supported by the swift recovery of other commodities such as copper, coal and oil that make up a small proportion of the ASX 200 miners’ materials portfolios.
Iron ore miners are one of few businesses that have been able to maintain their dividends amidst the coronavirus pandemic. For another top dividend share, don’t miss the free report below.
NEW: Expert names top dividend stock for 2020 (free report)
When our resident dividend expert Edward Vesely has a stock tip, it can pay to listen. After all, he’s the investing genius that runs Motley Fool Dividend Investor, the newsletter service that has picked huge winners like Dicker Data (+92%), SDI Limited (+53%) and National Storage (+35%).*
Edward has just named what he believes is the number one ASX dividend stock to buy for 2020.
This fully franked “under the radar” company is currently trading more than 24% below its all-time high and paying a 6.7% grossed-up dividend.
The name of this dividend dynamo and the full investment case is revealed in this brand new free report.
But you will have to hurry — history has shown it can pay dividends to get in early to some of Edward’s stock picks, and this dividend stock is already on the move.
More reading
- ASX 200 Weekly Wrap: ASX bulls crash through 6,000 points
- 3 high quality ASX dividend shares you can buy today
- 5 things to watch on the ASX 200 on Tuesday
- 2 strong ASX dividend shares to bolster your income
- Want high-paying dividends? Try Wesfarmers shares and these 2 other ASX options
Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Are the Rio Tinto, Fortescue and BHP share prices a buy right now? appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3h9ZHiQ
The Latest
-
Is the Woolworths share price a buy?
-
Cloudflare Sees Uptick in Cyber Attacks as Internet Usage Increases
-
SpringWorks (SWTX): A Rare Cancer Biotech with Potentially >50% Upside. Recommending BUY.
-
Which markets or industries do you see perform best in the next decades (geographic vs. industry focus vs. cap size)? How do you build this into a strategy and portfolio to maximize expected risk-adjusted future returns?